Picture of CytoMed Therapeutics logo

GDTC CytoMed Therapeutics Cashflow Statement

0.000.00%
us flag iconLast trade - 00:00
HealthcareMicro Cap

Annual cashflow statement for CytoMed Therapeutics, fiscal year end - December 31st, SGD millions except per share, conversion factor applied.

2019
December 31st
C2020
December 31st
2021
December 31st
2022
December 31st
Period Length:12 M12 M12 M12 M
Source:PROSPECTUS/APROSPECTUS/APROSPECTUS/A20-F
Standards:
IFRS
IFRS
IFRS
IFRS
Status:FinalFinalFinalFinal
Net Income/Starting Line-0.851-1.94-2.05-3.13
Depreciation
Amortisation
Non-Cash Items0.0290.6780.3751.23
Unusual Items
Equity in Net Earnings/Losses
Other Non-Cash Items
Changes in Working Capital0.010.116-0.3660.112
Change in Accounts Receivable
Change in Inventories
Change in Payable / Accrued Expenses
Other Operating Cash Flow
Cash from Operating Activities-0.635-0.849-1.71-1.4
Capital Expenditures-1.17-0.265-0.582-0.474
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items0-0.248-0.2410
Sale of Fixed Assets
Sale/Maturity of Investment
Change in Net Investments
Purchase of Investments
Cash from Investing Activities-1.17-0.513-0.824-0.473
Financing Cash Flow Items-0.027-0.1061.88-0.125
Other Financing Cash Flow
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities1.191.884.170.969
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash-0.6160.5141.63-0.933